Poor
Not Aligned
Patient Risk:
High
Summary
Core atorvastatin (Lipitor) mechanism and muscle-related risk are supported, but multiple garlic-related claims (effects, interactions, and increased risks) are not supported by the provided FDA-approved label sections, substantially reducing alignment.
Category Scores
Accurate Statements
Lipitor (atorvastatin) works by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action: describes inhibition of HMG-CoA reductase and cholesterol synthesis in the liver.
Lipitor has been shown to reduce LDL (bad) cholesterol levels.
12.1 Mechanism of Action: describes reductions in plasma cholesterol/lipoproteins and reduction of LDL-C.
Lipitor has been associated with muscle damage (rhabdomyolysis).
5.1 Skeletal Muscle: includes rare cases of rhabdomyolysis.
Unsupported Statements
Lipitor is commonly prescribed to people with high cholesterol, heart disease, or those at risk of developing these conditions.
The provided label sections support indications for hyperlipidemia and cardiovascular risk reduction, but do not support the characterization of how 'commonly prescribed' it is.
Lipitor has been shown to improve cardiovascular health.
Label provided supports reduction of specific cardiovascular outcomes (e.g., MI, stroke, revascularization/angina), but does not state the broad phrasing 'improve cardiovascular health.'
Garlic may help reduce LDL cholesterol by inhibiting the production of cholesterol in the liver.
No garlic-related content is present in the provided label sections.
Garlic has antioxidant properties that may help protect against heart disease.
No garlic-related content is present in the provided label sections.
Combining garlic with Lipitor may increase the risk of side effects.
No garlic-specific combination risks are stated in the provided label sections.
Garlic may increase the risk of bleeding when taken with anticoagulant medications like Lipitor.
No garlic-related bleeding/anticoagulant interaction statements are present in the provided label sections.
Garlic has anticoagulant properties that may interact with Lipitor's anticoagulant effects.
No garlic-related content is present, and the provided label sections do not describe any anticoagulant effect of Lipitor.
Combining garlic with Lipitor may increase the risk of muscle damage.
Label provided discusses increased myopathy/rhabdomyolysis risk with specific interacting drugs, but does not mention garlic.
Combining garlic with Lipitor may increase the risk of liver damage.
Label provided discusses statin-associated liver dysfunction, but does not mention garlic or any garlic-specific combination effects.
Garlic and Lipitor can cause liver damage, particularly when taken in high doses.
No garlic-related content is present in the provided label sections.
The combination of garlic and Lipitor may increase the risk of liver failure.
No garlic-specific combination risks, and no mention of garlic, are present in the provided label sections.
Garlic may interact with other medications, including blood thinners.
No garlic-related interaction statements are present in the provided label sections.
Garlic may interact with other medications, including diabetes medications.
No garlic-related interaction statements are present in the provided label sections.
Garlic may interact with other medications, including blood pressure medications.
No garlic-related interaction statements are present in the provided label sections.
Combining garlic with Lipitor may increase the risk of interactions with other medications.
Provided label sections list interactions for specific agents, but do not mention garlic.
The potential risks of combining garlic with Lipitor are not well understood.
The provided label sections do not address garlic-Lipitor risk or the degree of understanding.
Contradictions
Important Omissions
No label-supported, garlic-free interaction details were provided (e.g., specific interacting drugs listed in the provided label sections such as cyclosporine, strong CYP3A4 inhibitors, fibric acid derivatives, niacin) that would be relevant to Lipitor drug-drug interaction counseling.
Importance:
Moderate
No label-supported monitoring recommendations for muscle effects (e.g., prompt reporting of muscle pain/weakness; discontinuation for suspected myopathy) were included.
Importance:
Moderate
No label-supported liver monitoring recommendations (e.g., LFTs prior to and at 12 weeks after initiation and after dose increases; monitoring if transaminases increase; cautions/contraindications for active liver disease) were included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple garlic-related effect/interaction and increased-risk claims (bleeding, muscle damage, liver damage/failure, medication interactions) are not supported by the provided FDA-approved Lipitor labeling sections; such unsupported counseling could mislead regarding risks/necessity of avoiding or monitoring the combination.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Garlic-related claims (mechanism, cardiovascular protection, and multiple interaction/increased-risk statements) are unsupported by the provided FDA-approved Lipitor label sections.
Suggested Improvement
Remove or rewrite garlic-related claims to reflect only label-supported atorvastatin information. If discussing interactions, restrict to label-listed interacting agents and label-supported monitoring/warnings (e.g., specific statin myopathy/rhabdomyolysis and liver function monitoring guidance present in the provided sections).